Hmdb loader
You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on Human Metabolome Database.
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:51 UTC
Update Date2022-03-07 02:51:55 UTC
HMDB IDHMDB0015258
Secondary Accession Numbers
  • HMDB15258
Metabolite Identification
Common NameDutasteride
DescriptionDutasteride belongs to a class of drugs called 5-alpha-reductase inhibitors, which block the action of the 5-alpha-reductase enzymes that convert testosterone into dihydrotestosterone (DHT). Finasteride also belongs to this group, but while dutasteride inhibits both isoforms of 5-alpha reductase, finasteride inhibits only one. Even so, a clinical study done by GlaxoSmithKline, the EPICS trial, did not find dutasteride to be more effective than finasteride in treating BPH. [Wikipedia ]
Structure
Data?1582753276
Synonyms
ValueSource
(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideChEBI
alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidideChEBI
AvodartKegg
(5a,17b)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideGenerator
(5Α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideGenerator
a,a,a,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5a-androst-1-ene-17b-carboxy-2',5'-xylidideGenerator
Α,α,α,alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5α-androst-1-ene-17β-carboxy-2',5'-xylidideGenerator
17beta-N-(2,5-Bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-oneHMDB
745, GGHMDB
Chemical FormulaC27H30F6N2O2
Average Molecular Weight528.5297
Monoisotopic Molecular Weight528.221147444
IUPAC Name(1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-3-ene-14-carboxamide
Traditional Namedutasteride
CAS Registry Number164656-23-9
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F
InChI Identifier
InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1
InChI KeyJWJOTENAMICLJG-QWBYCMEYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassAndrostane steroids
Direct ParentAndrogens and derivatives
Alternative Parents
Substituents
  • Androgen-skeleton
  • 3-oxosteroid
  • 3-oxo-4-azasteroid
  • 3-oxo-5-alpha-steroid
  • Oxosteroid
  • 4-azasteroid
  • Azasteroid
  • Trifluoromethylbenzene
  • Anilide
  • N-arylamide
  • Monocyclic benzene moiety
  • Benzenoid
  • Carboxamide group
  • Lactam
  • Secondary carboxylic acid amide
  • Azacycle
  • Carboxylic acid derivative
  • Organoheterocyclic compound
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Organic nitrogen compound
  • Carbonyl group
  • Hydrocarbon derivative
  • Organic oxide
  • Organopnictogen compound
  • Organic oxygen compound
  • Organofluoride
  • Organonitrogen compound
  • Organooxygen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.00091 g/LNot Available
LogP6.8Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.00091 g/LALOGPS
logP5.45ALOGPS
logP5.79ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)12.56ChemAxon
pKa (Strongest Basic)2.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 ŲChemAxon
Rotatable Bond Count4ChemAxon
Refractivity127.9 m³·mol⁻¹ChemAxon
Polarizability50.13 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M-2H]-249.16630932474
DeepCCS[M+Na]+223.18330932474
AllCCS[M+H]+219.232859911
AllCCS[M+H-H2O]+217.732859911
AllCCS[M+NH4]+220.632859911
AllCCS[M+Na]+221.032859911
AllCCS[M-H]-215.032859911
AllCCS[M+Na-2H]-216.032859911
AllCCS[M+HCOO]-217.432859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Dutasteride[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F3280.0Standard polar33892256
Dutasteride[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F3433.1Standard non polar33892256
Dutasteride[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])NC(=O)C=C[C@]4(C)[C@@]3([H])CC[C@]12C)C(=O)NC1=CC(=CC=C1C(F)(F)F)C(F)(F)F3508.2Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Dutasteride,1TMS,isomer #1C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F3284.2Semi standard non polar33892256
Dutasteride,1TMS,isomer #1C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F3296.4Standard non polar33892256
Dutasteride,1TMS,isomer #1C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F3763.8Standard polar33892256
Dutasteride,1TMS,isomer #2C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C3261.8Semi standard non polar33892256
Dutasteride,1TMS,isomer #2C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C3291.2Standard non polar33892256
Dutasteride,1TMS,isomer #2C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C3820.7Standard polar33892256
Dutasteride,2TMS,isomer #1C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C3188.4Semi standard non polar33892256
Dutasteride,2TMS,isomer #1C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C3383.5Standard non polar33892256
Dutasteride,2TMS,isomer #1C[C@]12CC[C@H]3[C@@H](CC[C@H]4N([Si](C)(C)C)C(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)N(C1=CC(C(F)(F)F)=CC=C1C(F)(F)F)[Si](C)(C)C3553.0Standard polar33892256
Dutasteride,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]123490.9Semi standard non polar33892256
Dutasteride,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]123483.3Standard non polar33892256
Dutasteride,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)N1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)[C@@H](C(=O)NC5=CC(C(F)(F)F)=CC=C5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]123841.1Standard polar33892256
Dutasteride,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F3463.5Semi standard non polar33892256
Dutasteride,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F3483.4Standard non polar33892256
Dutasteride,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F3881.9Standard polar33892256
Dutasteride,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F3548.1Semi standard non polar33892256
Dutasteride,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F3747.9Standard non polar33892256
Dutasteride,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)N(C(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4N([Si](C)(C)C(C)(C)C)C(=O)C=C[C@]4(C)[C@H]3CC[C@]12C)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F3673.9Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Dutasteride GC-MS (Non-derivatized) - 70eV, Positivesplash10-0r00-0695380000-37d765dda5ec5e49b0fd2017-09-01Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 10V, Positive-QTOFsplash10-004i-0010190000-3420a2295d7f96d1d3c82016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 20V, Positive-QTOFsplash10-0w4i-0566290000-0b4c4c43a1363f4cde3c2016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 40V, Positive-QTOFsplash10-0fka-2490010000-583fa26158a6ee3f69db2016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 10V, Negative-QTOFsplash10-004i-0000090000-6590720379fb16a92f432016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 20V, Negative-QTOFsplash10-004i-1050090000-ceadcb8345b10a444f0f2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 40V, Negative-QTOFsplash10-0kbf-2190000000-a71ffb6ab0e5ccfce59b2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 10V, Positive-QTOFsplash10-004i-0001090000-69b701f7be2c2462c87c2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 20V, Positive-QTOFsplash10-00b9-0594370000-8a9228b409aa1db367662021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 40V, Positive-QTOFsplash10-00xr-0590000000-e41abf0c7f5b9d8fd56d2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 10V, Negative-QTOFsplash10-004i-0000090000-754362aa78fcb98858062021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 20V, Negative-QTOFsplash10-004i-1020090000-9af76f2aa77fb2cdadf52021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Dutasteride 40V, Negative-QTOFsplash10-004i-0040090000-5354ee6cb84f313f4a812021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Extracellular
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01126 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01126 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01126
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID5293502
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkDutasteride
METLIN IDNot Available
PubChem Compound6918296
PDB IDNot Available
ChEBI ID521033
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566 ]
  2. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347 ]
  3. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
  4. Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
  5. Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
  6. Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
  7. Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.

Enzymes

General function:
Involved in 3-oxo-5-alpha-steroid 4-dehydrogenase activity
Specific function:
Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene Name:
SRD5A2
Uniprot ID:
P31213
Molecular weight:
28407.035
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Rathnayake D, Sinclair R: Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. [PubMed:20426708 ]
  3. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors. Steroids. 2010 Feb;75(2):109-53. doi: 10.1016/j.steroids.2009.10.005. Epub 2009 Oct 30. [PubMed:19879888 ]
  4. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
  5. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. [PubMed:19543428 ]
  6. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566 ]
  7. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. [PubMed:16818707 ]
  8. Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. [PubMed:19200641 ]
  9. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347 ]
General function:
Involved in 3-oxo-5-alpha-steroid 4-dehydrogenase activity
Specific function:
Converts testosterone into 5-alpha-dihydrotestosterone and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
Gene Name:
SRD5A1
Uniprot ID:
P18405
Molecular weight:
29458.18
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9. [PubMed:16818707 ]
  3. Rathnayake D, Sinclair R: Male androgenetic alopecia. Expert Opin Pharmacother. 2010 Jun;11(8):1295-304. doi: 10.1517/14656561003752730. [PubMed:20426708 ]
  4. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors. Steroids. 2010 Feb;75(2):109-53. doi: 10.1016/j.steroids.2009.10.005. Epub 2009 Oct 30. [PubMed:19879888 ]
  5. Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12. [PubMed:19707263 ]
  6. Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. [PubMed:19543428 ]
  7. Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders. Drugs. 2008;68(4):463-85. [PubMed:18318566 ]
  8. Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. [PubMed:19200641 ]
  9. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16. [PubMed:19091347 ]
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular weight:
57255.585
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular weight:
57108.065
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]